AstraZeneca

The “on-again-off-again” courtship of British pharma AstraZeneca (NYSE: AZN) by U.S. drugmaker, Pfizer (NYSE: PFE), was on again, according to a statement from Pfizer. The renewed offer of almost $100 billion may, according to analysts, go over that amount. AstraZeneca rebuffed Pfizer’s $98.9...

U.S. stocks inched higher as Apple's strong earnings reported on Wednesday proved to be not enough to ease fears over an escalating tension between Russia and Ukraine. Reports surfaced of escalated troop movements in Ukraine while Russia began military drills near the Ukraine border. After...

According to Reuters, big pharma giant, Pfizer (NYSE: PFE) is considering a $100 billion bid for overseas rival AstraZeneca (NYSE: AZN). Reuters gives credit to Britain’s Sunday Times that cited  senior investment bankers who said that conversations between the two companies had taken place...

U.S. stocks were mixed as investors continue to follow the standoff in Ukraine and digested February's jobs report which indicated that harsh winter weather could be the culprit behind weakness seen in recent economic data reports. The S&P 500 trading at new all time highs at 1,883.57 but...

January, with its five percent correction, is behind us, and earnings continue to roll out this week, whether or not the groundhog saw his shadow. Highlights will include quarterly results from General Motors (NYSE: GM), Merck (NYSE: MRK), Philip Morris (NYSE: PM) and Walt Disney (NYSE: DIS),...

Major indices barely budged Thursday following yesterday's monster rally after the Fed announced it will begin tapering. Overall volume was below average which is typical in the final trading days of the year. Next week will be shortened as investors break for Christmas and a week later for new...

The earnings crunch rolls on. This week's highlights include quarterly reports from the two biggest companies by market capitalization, Apple and Exxon Mobil, which are expect to post declining earnings. Per-share earnings from General Motors are expected to be the same as a year ago, and...

On Sunday, after months of trying to work out a deal, Amgen (NASDAQ: AMGN) and Onyx (NASDAQ: ONXX) announced that Amgen will acquire Onyx for $125 per share valuing the deal as $10.4 billion. The announcement is about as much of a surprise as those two flirtatious coworkers that later told...

The oil and gas industry will be well represented on this week's earnings stage, with reports due from supermajors Exxon Mobil (NYSE: XOM) and Chevron (NYSE: CVX), and many others in the field. Viacom (NYSE: VIAB) and Comcast (NASDAQ: CMCSA) will be the highlights among the various media companies...

Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new team includes recommendations to buy shares of Antares Pharma (NASDAQ: ATRS), Intercept Pharmaceuticals (NASDAQ: ICPT), Questcor Pharmaceuticals (NASDAQ: QCOR) and ViroPharma...

AstraZeneca (NYSE: AZN) announced Monday that it will purchase privately held Pearl Therapeutics for up to $1.15 billion in its continuing drive to reinvigorate its product pipeline. The acquisition of the U.S. based respiratory drug specialist Pearl gives AstraZeneca a foothold in the newest...

Insiders may sell shares for any number of reasons, but conventional wisdom is that insiders really only buy shares of a company for one reason -- they believe the stock price will move higher and they want to profit from it. Pullbacks and sell-offs provide a perfect opportunity for investors who...